Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2012. The report details a specific share repurchase transaction executed on December 4, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 695,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,355.5 pence per share; lowest price paid was 1,342.5 pence per share.
- Treasury Holdings: 490,140,427 shares held in Treasury (9.08% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 9.98% of total voting rights.
- Shares in Issue: 4,909,117,589 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 695,000 repurchased shares. The filing does not provide comparative financial data against prior periods to assess broader operational changes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 695,000 share repurchase based on the weighted average price between 1,342.5 and 1,355.5 pence.
- Confirm the updated total issued share capital following the cancellation of the repurchased shares.
- Review the remaining authorization for share buybacks under the mandate granted on May 3, 2012.
- Check subsequent filings for the settlement status of any shares purchased but not yet settled as of the report date.